Richard MS - Mustang Bio Head Development
| MBIO Stock | USD 0.32 0.03 8.57% |
Executive
Richard MS is Head Development of Mustang Bio
| Address | 377 Plantation Street, Worcester, MA, United States, 01605 |
| Phone | 781 652 4500 |
| Web | https://www.mustangbio.com |
Mustang Bio Management Efficiency
The company has return on total asset (ROA) of (0.5756) % which means that it has lost $0.5756 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2244) %, meaning that it created substantial loss on money invested by shareholders. Mustang Bio's management efficiency ratios could be used to measure how well Mustang Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of April 2024, Return On Tangible Assets is likely to grow to -2.76. In addition to that, Return On Capital Employed is likely to grow to -20.32. At this time, Mustang Bio's Net Tangible Assets are very stable compared to the past year. As of the 27th of April 2024, Non Current Assets Total is likely to grow to about 8.8 M, while Total Assets are likely to drop about 16.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ferdinand Verdonck | Affimed NV | 76 | |
| Dr MPH | Dermata Therapeutics | 59 | |
| Maria MBA | Dermata Therapeutics | 73 | |
| Michael Louie | Kodiak Sciences | N/A | |
| John Lunger | Adaptimmune Therapeutics Plc | 55 | |
| Robert Homolka | Neurobo Pharmaceuticals | N/A | |
| Wendy CPA | Akari Therapeutics PLC | 57 | |
| MPH MD | Salarius Pharmaceuticals | N/A | |
| Daniel Hood | Achilles Therapeutics PLC | N/A | |
| Pablo MD | Kodiak Sciences | N/A | |
| Philippe Ledru | Aptose Biosciences | 56 | |
| Robyn Hunter | Fortress Biotech Pref | 61 | |
| Tariq Ahmed | Achilles Therapeutics PLC | N/A | |
| Pramod Gupta | Unicycive Therapeutics | 64 | |
| Shree Patel | Achilles Therapeutics PLC | N/A | |
| Roger BSc | Aptose Biosciences | N/A | |
| James Taylor | Achilles Therapeutics PLC | 63 | |
| BethAnne Lang | Akari Therapeutics PLC | N/A | |
| Stephen Raillard | Kodiak Sciences | N/A | |
| Mary Sandin | Affimed NV | N/A | |
| BA ACA | Adaptimmune Therapeutics Plc | 54 | |
Management Performance
| Return On Equity | -2.22 | ||||
| Return On Asset | -0.58 |
Mustang Bio Leadership Team
Elected by the shareholders, the Mustang Bio's board of directors comprises two types of representatives: Mustang Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mustang. The board's role is to monitor Mustang Bio's management team and ensure that shareholders' interests are well served. Mustang Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mustang Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eliot CPA, Interim Officer | ||
| Richard MS, Head Development | ||
| Manuel MD, CEO, President | ||
| Matthew JD, VP Counsel | ||
| Bruce MD, Senior Development | ||
| Lynn MS, VP Affairs | ||
| Peter Carney, Controller Officer | ||
| James Murphy, Interim Officer | ||
| MS MBA, VP Leadership | ||
| Robyn Hunter, Co Sec | ||
| Scott MBA, Ex Management | ||
| Knut Niss, Chief Officer | ||
| Greg MS, Chief Officer | ||
| Michael Esq, Executive Chairman | ||
| Debra SPHR, Senior Resources |
Mustang Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mustang Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.22 | ||||
| Return On Asset | -0.58 | ||||
| Current Valuation | (117.97 K) | ||||
| Shares Outstanding | 9.54 M | ||||
| Shares Owned By Insiders | 22.76 % | ||||
| Shares Owned By Institutions | 10.10 % | ||||
| Number Of Shares Shorted | 136.52 K | ||||
| Price To Earning | (11.40) X | ||||
| Price To Book | 42.91 X | ||||
| EBITDA | (48.5 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mustang Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Mustang Stock, please use our How to Invest in Mustang Bio guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Mustang Stock analysis
When running Mustang Bio's price analysis, check to measure Mustang Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mustang Bio is operating at the current time. Most of Mustang Bio's value examination focuses on studying past and present price action to predict the probability of Mustang Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mustang Bio's price. Additionally, you may evaluate how the addition of Mustang Bio to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Mustang Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mustang Bio. If investors know Mustang will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mustang Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.01) | Revenue Per Share (0) | Return On Assets (0.58) | Return On Equity (2.22) |
The market value of Mustang Bio is measured differently than its book value, which is the value of Mustang that is recorded on the company's balance sheet. Investors also form their own opinion of Mustang Bio's value that differs from its market value or its book value, called intrinsic value, which is Mustang Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mustang Bio's market value can be influenced by many factors that don't directly affect Mustang Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mustang Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mustang Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mustang Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.